nodes	percent_of_prediction	percent_of_DWPC	metapath
Boceprevir—ABCB1—esophageal cancer	0.396	1	CbGaD
Boceprevir—CTSL—exocrine gland—esophageal cancer	0.0138	0.0894	CbGeAlD
Boceprevir—CTSS—exocrine gland—esophageal cancer	0.00911	0.059	CbGeAlD
Boceprevir—CTSL—neck—esophageal cancer	0.00882	0.0572	CbGeAlD
Boceprevir—CTSV—bronchus—esophageal cancer	0.00724	0.0469	CbGeAlD
Boceprevir—CMA1—smooth muscle tissue—esophageal cancer	0.00677	0.0438	CbGeAlD
Boceprevir—CTSV—trachea—esophageal cancer	0.0065	0.0421	CbGeAlD
Boceprevir—CTSL—epithelium—esophageal cancer	0.006	0.0389	CbGeAlD
Boceprevir—CTSL—bronchus—esophageal cancer	0.00591	0.0383	CbGeAlD
Boceprevir—CTSS—neck—esophageal cancer	0.00583	0.0377	CbGeAlD
Boceprevir—CTSL—smooth muscle tissue—esophageal cancer	0.00579	0.0375	CbGeAlD
Boceprevir—CMA1—digestive system—esophageal cancer	0.00534	0.0346	CbGeAlD
Boceprevir—CTSL—trachea—esophageal cancer	0.00531	0.0344	CbGeAlD
Boceprevir—CTSV—lung—esophageal cancer	0.00467	0.0303	CbGeAlD
Boceprevir—CTSL—digestive system—esophageal cancer	0.00457	0.0296	CbGeAlD
Boceprevir—CMA1—lung—esophageal cancer	0.00446	0.0289	CbGeAlD
Boceprevir—CTSK—bronchus—esophageal cancer	0.00446	0.0289	CbGeAlD
Boceprevir—CTSK—smooth muscle tissue—esophageal cancer	0.00436	0.0282	CbGeAlD
Boceprevir—CTSK—trachea—esophageal cancer	0.004	0.0259	CbGeAlD
Boceprevir—CTSS—bronchus—esophageal cancer	0.0039	0.0253	CbGeAlD
Boceprevir—CTSS—smooth muscle tissue—esophageal cancer	0.00382	0.0247	CbGeAlD
Boceprevir—CTSL—lung—esophageal cancer	0.00382	0.0247	CbGeAlD
Boceprevir—CTSS—trachea—esophageal cancer	0.00351	0.0227	CbGeAlD
Boceprevir—CTSK—digestive system—esophageal cancer	0.00344	0.0223	CbGeAlD
Boceprevir—CMA1—lymph node—esophageal cancer	0.00305	0.0198	CbGeAlD
Boceprevir—CTSS—digestive system—esophageal cancer	0.00302	0.0195	CbGeAlD
Boceprevir—CTSK—lung—esophageal cancer	0.00287	0.0186	CbGeAlD
Boceprevir—Telaprevir—ABCB1—esophageal cancer	0.00276	1	CrCbGaD
Boceprevir—CTSL—lymph node—esophageal cancer	0.00261	0.0169	CbGeAlD
Boceprevir—CTSS—lung—esophageal cancer	0.00252	0.0163	CbGeAlD
Boceprevir—CTSK—lymph node—esophageal cancer	0.00197	0.0127	CbGeAlD
Boceprevir—CTSS—lymph node—esophageal cancer	0.00172	0.0112	CbGeAlD
Boceprevir—CYP3A5—digestive system—esophageal cancer	0.001	0.00649	CbGeAlD
Boceprevir—CYP3A5—lung—esophageal cancer	0.000837	0.00542	CbGeAlD
Boceprevir—CYP3A4—digestive system—esophageal cancer	0.000752	0.00487	CbGeAlD
Boceprevir—ABCB1—epithelium—esophageal cancer	0.000699	0.00453	CbGeAlD
Boceprevir—ABCB1—trachea—esophageal cancer	0.000618	0.00401	CbGeAlD
Boceprevir—ABCB1—digestive system—esophageal cancer	0.000532	0.00345	CbGeAlD
Boceprevir—Pain in extremity—Capecitabine—esophageal cancer	0.000519	0.00236	CcSEcCtD
Boceprevir—Hepatobiliary disease—Cisplatin—esophageal cancer	0.000513	0.00234	CcSEcCtD
Boceprevir—Migraine—Capecitabine—esophageal cancer	0.000511	0.00233	CcSEcCtD
Boceprevir—Irritability—Capecitabine—esophageal cancer	0.000495	0.00226	CcSEcCtD
Boceprevir—Mood swings—Capecitabine—esophageal cancer	0.000491	0.00224	CcSEcCtD
Boceprevir—Dehydration—Capecitabine—esophageal cancer	0.000482	0.0022	CcSEcCtD
Boceprevir—Mouth ulceration—Methotrexate—esophageal cancer	0.000481	0.00219	CcSEcCtD
Boceprevir—Neoplasm—Methotrexate—esophageal cancer	0.000481	0.00219	CcSEcCtD
Boceprevir—Urinary tract disorder—Cisplatin—esophageal cancer	0.000481	0.00219	CcSEcCtD
Boceprevir—Connective tissue disorder—Cisplatin—esophageal cancer	0.000478	0.00218	CcSEcCtD
Boceprevir—Urethral disorder—Cisplatin—esophageal cancer	0.000477	0.00217	CcSEcCtD
Boceprevir—Dry skin—Capecitabine—esophageal cancer	0.000476	0.00217	CcSEcCtD
Boceprevir—Abdominal pain upper—Capecitabine—esophageal cancer	0.000474	0.00216	CcSEcCtD
Boceprevir—Hypokalaemia—Capecitabine—esophageal cancer	0.000472	0.00215	CcSEcCtD
Boceprevir—Visual impairment—Cisplatin—esophageal cancer	0.000469	0.00214	CcSEcCtD
Boceprevir—Breast disorder—Capecitabine—esophageal cancer	0.000469	0.00214	CcSEcCtD
Boceprevir—Nasopharyngitis—Capecitabine—esophageal cancer	0.000464	0.00211	CcSEcCtD
Boceprevir—Sepsis—Methotrexate—esophageal cancer	0.000462	0.0021	CcSEcCtD
Boceprevir—Gastritis—Capecitabine—esophageal cancer	0.000459	0.00209	CcSEcCtD
Boceprevir—Muscular weakness—Capecitabine—esophageal cancer	0.000458	0.00208	CcSEcCtD
Boceprevir—Eye disorder—Cisplatin—esophageal cancer	0.000455	0.00207	CcSEcCtD
Boceprevir—Tinnitus—Cisplatin—esophageal cancer	0.000454	0.00207	CcSEcCtD
Boceprevir—Lymphadenopathy—Methotrexate—esophageal cancer	0.000453	0.00206	CcSEcCtD
Boceprevir—Flushing—Cisplatin—esophageal cancer	0.000452	0.00206	CcSEcCtD
Boceprevir—Cardiac disorder—Cisplatin—esophageal cancer	0.000452	0.00206	CcSEcCtD
Boceprevir—Abdominal distension—Capecitabine—esophageal cancer	0.000451	0.00206	CcSEcCtD
Boceprevir—Influenza—Capecitabine—esophageal cancer	0.000448	0.00204	CcSEcCtD
Boceprevir—Dysphagia—Capecitabine—esophageal cancer	0.000448	0.00204	CcSEcCtD
Boceprevir—ABCB1—lung—esophageal cancer	0.000444	0.00288	CbGeAlD
Boceprevir—Diabetes mellitus—Methotrexate—esophageal cancer	0.000444	0.00202	CcSEcCtD
Boceprevir—Immune system disorder—Cisplatin—esophageal cancer	0.00044	0.002	CcSEcCtD
Boceprevir—Mediastinal disorder—Cisplatin—esophageal cancer	0.000439	0.002	CcSEcCtD
Boceprevir—Arrhythmia—Cisplatin—esophageal cancer	0.000435	0.00198	CcSEcCtD
Boceprevir—Bronchitis—Capecitabine—esophageal cancer	0.000431	0.00196	CcSEcCtD
Boceprevir—Alopecia—Cisplatin—esophageal cancer	0.00043	0.00196	CcSEcCtD
Boceprevir—Abdominal discomfort—Capecitabine—esophageal cancer	0.00043	0.00196	CcSEcCtD
Boceprevir—Pancytopenia—Capecitabine—esophageal cancer	0.000426	0.00194	CcSEcCtD
Boceprevir—Erythema—Cisplatin—esophageal cancer	0.000424	0.00193	CcSEcCtD
Boceprevir—Malnutrition—Cisplatin—esophageal cancer	0.000424	0.00193	CcSEcCtD
Boceprevir—Neutropenia—Capecitabine—esophageal cancer	0.000419	0.00191	CcSEcCtD
Boceprevir—Dysuria—Capecitabine—esophageal cancer	0.000419	0.00191	CcSEcCtD
Boceprevir—Flatulence—Cisplatin—esophageal cancer	0.000418	0.0019	CcSEcCtD
Boceprevir—Dermatitis exfoliative—Methotrexate—esophageal cancer	0.000409	0.00186	CcSEcCtD
Boceprevir—Photosensitivity reaction—Capecitabine—esophageal cancer	0.000409	0.00186	CcSEcCtD
Boceprevir—Muscle spasms—Cisplatin—esophageal cancer	0.000407	0.00186	CcSEcCtD
Boceprevir—Weight decreased—Capecitabine—esophageal cancer	0.000406	0.00185	CcSEcCtD
Boceprevir—Hyperglycaemia—Capecitabine—esophageal cancer	0.000404	0.00184	CcSEcCtD
Boceprevir—Pneumonia—Capecitabine—esophageal cancer	0.000402	0.00183	CcSEcCtD
Boceprevir—Infestation NOS—Capecitabine—esophageal cancer	0.0004	0.00182	CcSEcCtD
Boceprevir—Infestation—Capecitabine—esophageal cancer	0.0004	0.00182	CcSEcCtD
Boceprevir—Vision blurred—Cisplatin—esophageal cancer	0.000399	0.00182	CcSEcCtD
Boceprevir—Depression—Capecitabine—esophageal cancer	0.000399	0.00182	CcSEcCtD
Boceprevir—Stevens-Johnson syndrome—Capecitabine—esophageal cancer	0.000396	0.00181	CcSEcCtD
Boceprevir—Lethargy—Methotrexate—esophageal cancer	0.000394	0.0018	CcSEcCtD
Boceprevir—Ill-defined disorder—Cisplatin—esophageal cancer	0.000393	0.00179	CcSEcCtD
Boceprevir—Neuropathy peripheral—Capecitabine—esophageal cancer	0.000392	0.00179	CcSEcCtD
Boceprevir—Anaemia—Cisplatin—esophageal cancer	0.000392	0.00178	CcSEcCtD
Boceprevir—Stomatitis—Capecitabine—esophageal cancer	0.00039	0.00178	CcSEcCtD
Boceprevir—Urinary tract infection—Capecitabine—esophageal cancer	0.000389	0.00177	CcSEcCtD
Boceprevir—Conjunctivitis—Capecitabine—esophageal cancer	0.000389	0.00177	CcSEcCtD
Boceprevir—Malaise—Cisplatin—esophageal cancer	0.000382	0.00174	CcSEcCtD
Boceprevir—Leukopenia—Cisplatin—esophageal cancer	0.000379	0.00173	CcSEcCtD
Boceprevir—Hepatobiliary disease—Capecitabine—esophageal cancer	0.000378	0.00172	CcSEcCtD
Boceprevir—Epistaxis—Capecitabine—esophageal cancer	0.000377	0.00172	CcSEcCtD
Boceprevir—Agranulocytosis—Capecitabine—esophageal cancer	0.000373	0.0017	CcSEcCtD
Boceprevir—Irritability—Methotrexate—esophageal cancer	0.000369	0.00168	CcSEcCtD
Boceprevir—Mood swings—Methotrexate—esophageal cancer	0.000366	0.00167	CcSEcCtD
Boceprevir—Myalgia—Cisplatin—esophageal cancer	0.000361	0.00164	CcSEcCtD
Boceprevir—Rhinitis—Capecitabine—esophageal cancer	0.00036	0.00164	CcSEcCtD
Boceprevir—Anxiety—Cisplatin—esophageal cancer	0.00036	0.00164	CcSEcCtD
Boceprevir—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.000358	0.00163	CcSEcCtD
Boceprevir—Hypoaesthesia—Capecitabine—esophageal cancer	0.000357	0.00163	CcSEcCtD
Boceprevir—Discomfort—Cisplatin—esophageal cancer	0.000357	0.00162	CcSEcCtD
Boceprevir—Pharyngitis—Capecitabine—esophageal cancer	0.000356	0.00162	CcSEcCtD
Boceprevir—Urinary tract disorder—Capecitabine—esophageal cancer	0.000354	0.00161	CcSEcCtD
Boceprevir—Oedema peripheral—Capecitabine—esophageal cancer	0.000354	0.00161	CcSEcCtD
Boceprevir—Connective tissue disorder—Capecitabine—esophageal cancer	0.000353	0.00161	CcSEcCtD
Boceprevir—Urethral disorder—Capecitabine—esophageal cancer	0.000352	0.0016	CcSEcCtD
Boceprevir—Breast disorder—Methotrexate—esophageal cancer	0.000349	0.00159	CcSEcCtD
Boceprevir—Visual impairment—Capecitabine—esophageal cancer	0.000346	0.00158	CcSEcCtD
Boceprevir—Infection—Cisplatin—esophageal cancer	0.000344	0.00157	CcSEcCtD
Boceprevir—Erythema multiforme—Capecitabine—esophageal cancer	0.000339	0.00155	CcSEcCtD
Boceprevir—Nervous system disorder—Cisplatin—esophageal cancer	0.000339	0.00155	CcSEcCtD
Boceprevir—Thrombocytopenia—Cisplatin—esophageal cancer	0.000339	0.00154	CcSEcCtD
Boceprevir—Tachycardia—Cisplatin—esophageal cancer	0.000338	0.00154	CcSEcCtD
Boceprevir—Skin disorder—Cisplatin—esophageal cancer	0.000336	0.00153	CcSEcCtD
Boceprevir—Eye disorder—Capecitabine—esophageal cancer	0.000335	0.00153	CcSEcCtD
Boceprevir—Tinnitus—Capecitabine—esophageal cancer	0.000335	0.00152	CcSEcCtD
Boceprevir—Hyperhidrosis—Cisplatin—esophageal cancer	0.000334	0.00152	CcSEcCtD
Boceprevir—Cardiac disorder—Capecitabine—esophageal cancer	0.000333	0.00152	CcSEcCtD
Boceprevir—Flushing—Capecitabine—esophageal cancer	0.000333	0.00152	CcSEcCtD
Boceprevir—Eosinophilia—Methotrexate—esophageal cancer	0.00033	0.00151	CcSEcCtD
Boceprevir—Pancreatitis—Methotrexate—esophageal cancer	0.000327	0.00149	CcSEcCtD
Boceprevir—Angiopathy—Capecitabine—esophageal cancer	0.000326	0.00148	CcSEcCtD
Boceprevir—Immune system disorder—Capecitabine—esophageal cancer	0.000324	0.00148	CcSEcCtD
Boceprevir—Mediastinal disorder—Capecitabine—esophageal cancer	0.000323	0.00147	CcSEcCtD
Boceprevir—Hypotension—Cisplatin—esophageal cancer	0.000323	0.00147	CcSEcCtD
Boceprevir—Chills—Capecitabine—esophageal cancer	0.000322	0.00147	CcSEcCtD
Boceprevir—Arrhythmia—Capecitabine—esophageal cancer	0.000321	0.00146	CcSEcCtD
Boceprevir—Abdominal discomfort—Methotrexate—esophageal cancer	0.00032	0.00146	CcSEcCtD
Boceprevir—Alopecia—Capecitabine—esophageal cancer	0.000317	0.00144	CcSEcCtD
Boceprevir—Pancytopenia—Methotrexate—esophageal cancer	0.000317	0.00144	CcSEcCtD
Boceprevir—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.000315	0.00144	CcSEcCtD
Boceprevir—Mental disorder—Capecitabine—esophageal cancer	0.000314	0.00143	CcSEcCtD
Boceprevir—Malnutrition—Capecitabine—esophageal cancer	0.000312	0.00142	CcSEcCtD
Boceprevir—Erythema—Capecitabine—esophageal cancer	0.000312	0.00142	CcSEcCtD
Boceprevir—Neutropenia—Methotrexate—esophageal cancer	0.000312	0.00142	CcSEcCtD
Boceprevir—Dysuria—Methotrexate—esophageal cancer	0.000312	0.00142	CcSEcCtD
Boceprevir—Paraesthesia—Cisplatin—esophageal cancer	0.000311	0.00142	CcSEcCtD
Boceprevir—Dyspnoea—Cisplatin—esophageal cancer	0.000308	0.0014	CcSEcCtD
Boceprevir—Flatulence—Capecitabine—esophageal cancer	0.000308	0.0014	CcSEcCtD
Boceprevir—Erectile dysfunction—Methotrexate—esophageal cancer	0.000307	0.0014	CcSEcCtD
Boceprevir—Dysgeusia—Capecitabine—esophageal cancer	0.000306	0.00139	CcSEcCtD
Boceprevir—Photosensitivity reaction—Methotrexate—esophageal cancer	0.000305	0.00139	CcSEcCtD
Boceprevir—ABCB1—lymph node—esophageal cancer	0.000304	0.00197	CbGeAlD
Boceprevir—Back pain—Capecitabine—esophageal cancer	0.000302	0.00138	CcSEcCtD
Boceprevir—Decreased appetite—Cisplatin—esophageal cancer	0.000301	0.00137	CcSEcCtD
Boceprevir—Muscle spasms—Capecitabine—esophageal cancer	0.0003	0.00137	CcSEcCtD
Boceprevir—Pneumonia—Methotrexate—esophageal cancer	0.000299	0.00136	CcSEcCtD
Boceprevir—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.000299	0.00136	CcSEcCtD
Boceprevir—Infestation NOS—Methotrexate—esophageal cancer	0.000298	0.00136	CcSEcCtD
Boceprevir—Infestation—Methotrexate—esophageal cancer	0.000298	0.00136	CcSEcCtD
Boceprevir—Depression—Methotrexate—esophageal cancer	0.000297	0.00135	CcSEcCtD
Boceprevir—Pain—Cisplatin—esophageal cancer	0.000296	0.00135	CcSEcCtD
Boceprevir—Stevens-Johnson syndrome—Methotrexate—esophageal cancer	0.000295	0.00134	CcSEcCtD
Boceprevir—Vision blurred—Capecitabine—esophageal cancer	0.000294	0.00134	CcSEcCtD
Boceprevir—Stomatitis—Methotrexate—esophageal cancer	0.00029	0.00132	CcSEcCtD
Boceprevir—Ill-defined disorder—Capecitabine—esophageal cancer	0.00029	0.00132	CcSEcCtD
Boceprevir—Conjunctivitis—Methotrexate—esophageal cancer	0.000289	0.00132	CcSEcCtD
Boceprevir—Anaemia—Capecitabine—esophageal cancer	0.000289	0.00132	CcSEcCtD
Boceprevir—Feeling abnormal—Cisplatin—esophageal cancer	0.000285	0.0013	CcSEcCtD
Boceprevir—Malaise—Capecitabine—esophageal cancer	0.000282	0.00128	CcSEcCtD
Boceprevir—Hepatobiliary disease—Methotrexate—esophageal cancer	0.000281	0.00128	CcSEcCtD
Boceprevir—Epistaxis—Methotrexate—esophageal cancer	0.000281	0.00128	CcSEcCtD
Boceprevir—Vertigo—Capecitabine—esophageal cancer	0.000281	0.00128	CcSEcCtD
Boceprevir—Syncope—Capecitabine—esophageal cancer	0.00028	0.00128	CcSEcCtD
Boceprevir—Leukopenia—Capecitabine—esophageal cancer	0.00028	0.00127	CcSEcCtD
Boceprevir—Agranulocytosis—Methotrexate—esophageal cancer	0.000278	0.00127	CcSEcCtD
Boceprevir—Palpitations—Capecitabine—esophageal cancer	0.000276	0.00126	CcSEcCtD
Boceprevir—Loss of consciousness—Capecitabine—esophageal cancer	0.000275	0.00125	CcSEcCtD
Boceprevir—Body temperature increased—Cisplatin—esophageal cancer	0.000273	0.00125	CcSEcCtD
Boceprevir—Cough—Capecitabine—esophageal cancer	0.000273	0.00124	CcSEcCtD
Boceprevir—Hypertension—Capecitabine—esophageal cancer	0.00027	0.00123	CcSEcCtD
Boceprevir—Myalgia—Capecitabine—esophageal cancer	0.000266	0.00121	CcSEcCtD
Boceprevir—Chest pain—Capecitabine—esophageal cancer	0.000266	0.00121	CcSEcCtD
Boceprevir—Arthralgia—Capecitabine—esophageal cancer	0.000266	0.00121	CcSEcCtD
Boceprevir—Pharyngitis—Methotrexate—esophageal cancer	0.000265	0.00121	CcSEcCtD
Boceprevir—Anxiety—Capecitabine—esophageal cancer	0.000265	0.00121	CcSEcCtD
Boceprevir—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.000264	0.0012	CcSEcCtD
Boceprevir—Urinary tract disorder—Methotrexate—esophageal cancer	0.000264	0.0012	CcSEcCtD
Boceprevir—Discomfort—Capecitabine—esophageal cancer	0.000263	0.0012	CcSEcCtD
Boceprevir—Urethral disorder—Methotrexate—esophageal cancer	0.000262	0.00119	CcSEcCtD
Boceprevir—Dry mouth—Capecitabine—esophageal cancer	0.00026	0.00119	CcSEcCtD
Boceprevir—Visual impairment—Methotrexate—esophageal cancer	0.000257	0.00117	CcSEcCtD
Boceprevir—Confusional state—Capecitabine—esophageal cancer	0.000257	0.00117	CcSEcCtD
Boceprevir—Hypersensitivity—Cisplatin—esophageal cancer	0.000255	0.00116	CcSEcCtD
Boceprevir—Infection—Capecitabine—esophageal cancer	0.000253	0.00115	CcSEcCtD
Boceprevir—Erythema multiforme—Methotrexate—esophageal cancer	0.000253	0.00115	CcSEcCtD
Boceprevir—Shock—Capecitabine—esophageal cancer	0.000251	0.00114	CcSEcCtD
Boceprevir—Nervous system disorder—Capecitabine—esophageal cancer	0.00025	0.00114	CcSEcCtD
Boceprevir—Eye disorder—Methotrexate—esophageal cancer	0.00025	0.00114	CcSEcCtD
Boceprevir—Thrombocytopenia—Capecitabine—esophageal cancer	0.00025	0.00114	CcSEcCtD
Boceprevir—Tinnitus—Methotrexate—esophageal cancer	0.000249	0.00113	CcSEcCtD
Boceprevir—Tachycardia—Capecitabine—esophageal cancer	0.000249	0.00113	CcSEcCtD
Boceprevir—Asthenia—Cisplatin—esophageal cancer	0.000248	0.00113	CcSEcCtD
Boceprevir—Cardiac disorder—Methotrexate—esophageal cancer	0.000248	0.00113	CcSEcCtD
Boceprevir—Skin disorder—Capecitabine—esophageal cancer	0.000248	0.00113	CcSEcCtD
Boceprevir—Hyperhidrosis—Capecitabine—esophageal cancer	0.000246	0.00112	CcSEcCtD
Boceprevir—Angiopathy—Methotrexate—esophageal cancer	0.000242	0.0011	CcSEcCtD
Boceprevir—Immune system disorder—Methotrexate—esophageal cancer	0.000241	0.0011	CcSEcCtD
Boceprevir—Mediastinal disorder—Methotrexate—esophageal cancer	0.000241	0.0011	CcSEcCtD
Boceprevir—Chills—Methotrexate—esophageal cancer	0.00024	0.00109	CcSEcCtD
Boceprevir—Hypotension—Capecitabine—esophageal cancer	0.000238	0.00109	CcSEcCtD
Boceprevir—Diarrhoea—Cisplatin—esophageal cancer	0.000237	0.00108	CcSEcCtD
Boceprevir—Alopecia—Methotrexate—esophageal cancer	0.000236	0.00108	CcSEcCtD
Boceprevir—Mental disorder—Methotrexate—esophageal cancer	0.000234	0.00107	CcSEcCtD
Boceprevir—Malnutrition—Methotrexate—esophageal cancer	0.000233	0.00106	CcSEcCtD
Boceprevir—Erythema—Methotrexate—esophageal cancer	0.000233	0.00106	CcSEcCtD
Boceprevir—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.000232	0.00106	CcSEcCtD
Boceprevir—Insomnia—Capecitabine—esophageal cancer	0.000231	0.00105	CcSEcCtD
Boceprevir—Paraesthesia—Capecitabine—esophageal cancer	0.000229	0.00104	CcSEcCtD
Boceprevir—Dysgeusia—Methotrexate—esophageal cancer	0.000228	0.00104	CcSEcCtD
Boceprevir—Dyspnoea—Capecitabine—esophageal cancer	0.000227	0.00104	CcSEcCtD
Boceprevir—Back pain—Methotrexate—esophageal cancer	0.000225	0.00102	CcSEcCtD
Boceprevir—Dyspepsia—Capecitabine—esophageal cancer	0.000224	0.00102	CcSEcCtD
Boceprevir—Decreased appetite—Capecitabine—esophageal cancer	0.000222	0.00101	CcSEcCtD
Boceprevir—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.00022	0.001	CcSEcCtD
Boceprevir—Vomiting—Cisplatin—esophageal cancer	0.00022	0.001	CcSEcCtD
Boceprevir—Fatigue—Capecitabine—esophageal cancer	0.00022	0.001	CcSEcCtD
Boceprevir—Vision blurred—Methotrexate—esophageal cancer	0.000219	0.000999	CcSEcCtD
Boceprevir—Rash—Cisplatin—esophageal cancer	0.000218	0.000994	CcSEcCtD
Boceprevir—Constipation—Capecitabine—esophageal cancer	0.000218	0.000993	CcSEcCtD
Boceprevir—Pain—Capecitabine—esophageal cancer	0.000218	0.000993	CcSEcCtD
Boceprevir—Dermatitis—Cisplatin—esophageal cancer	0.000218	0.000993	CcSEcCtD
Boceprevir—Ill-defined disorder—Methotrexate—esophageal cancer	0.000216	0.000983	CcSEcCtD
Boceprevir—Anaemia—Methotrexate—esophageal cancer	0.000215	0.000979	CcSEcCtD
Boceprevir—Feeling abnormal—Capecitabine—esophageal cancer	0.00021	0.000957	CcSEcCtD
Boceprevir—Malaise—Methotrexate—esophageal cancer	0.00021	0.000956	CcSEcCtD
Boceprevir—Vertigo—Methotrexate—esophageal cancer	0.000209	0.000952	CcSEcCtD
Boceprevir—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000209	0.00095	CcSEcCtD
Boceprevir—Leukopenia—Methotrexate—esophageal cancer	0.000208	0.000948	CcSEcCtD
Boceprevir—Nausea—Cisplatin—esophageal cancer	0.000205	0.000936	CcSEcCtD
Boceprevir—Cough—Methotrexate—esophageal cancer	0.000203	0.000925	CcSEcCtD
Boceprevir—Urticaria—Capecitabine—esophageal cancer	0.000203	0.000923	CcSEcCtD
Boceprevir—Body temperature increased—Capecitabine—esophageal cancer	0.000202	0.000918	CcSEcCtD
Boceprevir—Abdominal pain—Capecitabine—esophageal cancer	0.000202	0.000918	CcSEcCtD
Boceprevir—Arthralgia—Methotrexate—esophageal cancer	0.000198	0.000902	CcSEcCtD
Boceprevir—Chest pain—Methotrexate—esophageal cancer	0.000198	0.000902	CcSEcCtD
Boceprevir—Myalgia—Methotrexate—esophageal cancer	0.000198	0.000902	CcSEcCtD
Boceprevir—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.000197	0.000896	CcSEcCtD
Boceprevir—Discomfort—Methotrexate—esophageal cancer	0.000196	0.000891	CcSEcCtD
Boceprevir—Confusional state—Methotrexate—esophageal cancer	0.000191	0.000872	CcSEcCtD
Boceprevir—Infection—Methotrexate—esophageal cancer	0.000189	0.000859	CcSEcCtD
Boceprevir—Hypersensitivity—Capecitabine—esophageal cancer	0.000188	0.000856	CcSEcCtD
Boceprevir—Nervous system disorder—Methotrexate—esophageal cancer	0.000186	0.000848	CcSEcCtD
Boceprevir—Thrombocytopenia—Methotrexate—esophageal cancer	0.000186	0.000847	CcSEcCtD
Boceprevir—Skin disorder—Methotrexate—esophageal cancer	0.000184	0.00084	CcSEcCtD
Boceprevir—Hyperhidrosis—Methotrexate—esophageal cancer	0.000183	0.000836	CcSEcCtD
Boceprevir—Asthenia—Capecitabine—esophageal cancer	0.000183	0.000833	CcSEcCtD
Boceprevir—Pruritus—Capecitabine—esophageal cancer	0.00018	0.000822	CcSEcCtD
Boceprevir—Hypotension—Methotrexate—esophageal cancer	0.000177	0.000808	CcSEcCtD
Boceprevir—Diarrhoea—Capecitabine—esophageal cancer	0.000174	0.000795	CcSEcCtD
Boceprevir—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.000173	0.000788	CcSEcCtD
Boceprevir—Insomnia—Methotrexate—esophageal cancer	0.000172	0.000782	CcSEcCtD
Boceprevir—Paraesthesia—Methotrexate—esophageal cancer	0.00017	0.000777	CcSEcCtD
Boceprevir—Dyspnoea—Methotrexate—esophageal cancer	0.000169	0.000771	CcSEcCtD
Boceprevir—Dizziness—Capecitabine—esophageal cancer	0.000169	0.000768	CcSEcCtD
Boceprevir—Dyspepsia—Methotrexate—esophageal cancer	0.000167	0.000761	CcSEcCtD
Boceprevir—Decreased appetite—Methotrexate—esophageal cancer	0.000165	0.000752	CcSEcCtD
Boceprevir—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.000164	0.000747	CcSEcCtD
Boceprevir—Fatigue—Methotrexate—esophageal cancer	0.000164	0.000746	CcSEcCtD
Boceprevir—Pain—Methotrexate—esophageal cancer	0.000162	0.00074	CcSEcCtD
Boceprevir—Vomiting—Capecitabine—esophageal cancer	0.000162	0.000739	CcSEcCtD
Boceprevir—Rash—Capecitabine—esophageal cancer	0.000161	0.000732	CcSEcCtD
Boceprevir—Dermatitis—Capecitabine—esophageal cancer	0.000161	0.000732	CcSEcCtD
Boceprevir—Headache—Capecitabine—esophageal cancer	0.00016	0.000728	CcSEcCtD
Boceprevir—Feeling abnormal—Methotrexate—esophageal cancer	0.000156	0.000713	CcSEcCtD
Boceprevir—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000155	0.000707	CcSEcCtD
Boceprevir—Nausea—Capecitabine—esophageal cancer	0.000151	0.00069	CcSEcCtD
Boceprevir—Urticaria—Methotrexate—esophageal cancer	0.000151	0.000687	CcSEcCtD
Boceprevir—Body temperature increased—Methotrexate—esophageal cancer	0.00015	0.000684	CcSEcCtD
Boceprevir—Abdominal pain—Methotrexate—esophageal cancer	0.00015	0.000684	CcSEcCtD
Boceprevir—Hypersensitivity—Methotrexate—esophageal cancer	0.00014	0.000637	CcSEcCtD
Boceprevir—Asthenia—Methotrexate—esophageal cancer	0.000136	0.00062	CcSEcCtD
Boceprevir—Pruritus—Methotrexate—esophageal cancer	0.000134	0.000612	CcSEcCtD
Boceprevir—Diarrhoea—Methotrexate—esophageal cancer	0.00013	0.000592	CcSEcCtD
Boceprevir—Dizziness—Methotrexate—esophageal cancer	0.000126	0.000572	CcSEcCtD
Boceprevir—Vomiting—Methotrexate—esophageal cancer	0.000121	0.00055	CcSEcCtD
Boceprevir—Rash—Methotrexate—esophageal cancer	0.00012	0.000545	CcSEcCtD
Boceprevir—Dermatitis—Methotrexate—esophageal cancer	0.00012	0.000545	CcSEcCtD
Boceprevir—CMA1—Signaling Pathways—PSME1—esophageal cancer	0.000119	0.000526	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—PSME2—esophageal cancer	0.000119	0.000526	CbGpPWpGaD
Boceprevir—Headache—Methotrexate—esophageal cancer	0.000119	0.000542	CcSEcCtD
Boceprevir—CYP3A4—Phase 1 - Functionalization of compounds—PTGS1—esophageal cancer	0.000119	0.000524	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—ANXA1—esophageal cancer	0.000119	0.000523	CbGpPWpGaD
Boceprevir—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—esophageal cancer	0.000117	0.000517	CbGpPWpGaD
Boceprevir—CTSL—Innate Immune System—CDKN1A—esophageal cancer	0.000116	0.000511	CbGpPWpGaD
Boceprevir—CTSV—Innate Immune System—CDKN1A—esophageal cancer	0.000116	0.000511	CbGpPWpGaD
Boceprevir—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—esophageal cancer	0.000116	0.00051	CbGpPWpGaD
Boceprevir—CTSK—Innate Immune System—BCL2—esophageal cancer	0.000116	0.00051	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—SST—esophageal cancer	0.000116	0.000509	CbGpPWpGaD
Boceprevir—CYP3A5—Biological oxidations—CYP1B1—esophageal cancer	0.000115	0.000509	CbGpPWpGaD
Boceprevir—ABCB1—HIF-1-alpha transcription factor network—NOS2—esophageal cancer	0.000115	0.000506	CbGpPWpGaD
Boceprevir—CYP3A4—Biological oxidations—ADH7—esophageal cancer	0.000115	0.000505	CbGpPWpGaD
Boceprevir—CYP3A5—Metapathway biotransformation—CYP1B1—esophageal cancer	0.000114	0.000502	CbGpPWpGaD
Boceprevir—Nausea—Methotrexate—esophageal cancer	0.000113	0.000514	CcSEcCtD
Boceprevir—CMA1—Signaling Pathways—GHRL—esophageal cancer	0.000113	0.000496	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—NOTCH3—esophageal cancer	0.000113	0.000496	CbGpPWpGaD
Boceprevir—CTSK—Innate Immune System—ERBB2—esophageal cancer	0.000112	0.000495	CbGpPWpGaD
Boceprevir—CTSL—Adaptive Immune System—CDKN1A—esophageal cancer	0.000111	0.00049	CbGpPWpGaD
Boceprevir—CTSV—Adaptive Immune System—CDKN1A—esophageal cancer	0.000111	0.00049	CbGpPWpGaD
Boceprevir—CTSS—Innate Immune System—CASP8—esophageal cancer	0.000111	0.000489	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—FBXW7—esophageal cancer	0.000111	0.000488	CbGpPWpGaD
Boceprevir—CTSS—Innate Immune System—CREBBP—esophageal cancer	0.00011	0.000487	CbGpPWpGaD
Boceprevir—CTSL—Immune System—TLR4—esophageal cancer	0.00011	0.000487	CbGpPWpGaD
Boceprevir—CTSV—Immune System—TLR4—esophageal cancer	0.00011	0.000487	CbGpPWpGaD
Boceprevir—CTSL—Innate Immune System—EP300—esophageal cancer	0.00011	0.000486	CbGpPWpGaD
Boceprevir—CTSV—Innate Immune System—EP300—esophageal cancer	0.00011	0.000486	CbGpPWpGaD
Boceprevir—CYP3A5—Biological oxidations—CYP19A1—esophageal cancer	0.000109	0.000478	CbGpPWpGaD
Boceprevir—CTSK—Adaptive Immune System—ERBB2—esophageal cancer	0.000108	0.000475	CbGpPWpGaD
Boceprevir—CYP3A5—Metapathway biotransformation—CYP19A1—esophageal cancer	0.000107	0.000472	CbGpPWpGaD
Boceprevir—ABCB1—HIF-1-alpha transcription factor network—CREBBP—esophageal cancer	0.000103	0.000455	CbGpPWpGaD
Boceprevir—CYP3A4—Phase 1 - Functionalization of compounds—CYP1B1—esophageal cancer	0.000101	0.000445	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—NOTCH2—esophageal cancer	0.000101	0.000445	CbGpPWpGaD
Boceprevir—CYP3A4—Biological oxidations—ADH1B—esophageal cancer	0.000101	0.000443	CbGpPWpGaD
Boceprevir—CTSS—Immune System—ABL1—esophageal cancer	9.94e-05	0.000438	CbGpPWpGaD
Boceprevir—CTSK—Innate Immune System—CDKN1A—esophageal cancer	9.6e-05	0.000423	CbGpPWpGaD
Boceprevir—CTSS—Innate Immune System—BCL2—esophageal cancer	9.53e-05	0.00042	CbGpPWpGaD
Boceprevir—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—esophageal cancer	9.5e-05	0.000419	CbGpPWpGaD
Boceprevir—CTSL—Immune System—CASP8—esophageal cancer	9.47e-05	0.000417	CbGpPWpGaD
Boceprevir—CTSV—Immune System—CASP8—esophageal cancer	9.47e-05	0.000417	CbGpPWpGaD
Boceprevir—CTSV—Immune System—CREBBP—esophageal cancer	9.43e-05	0.000416	CbGpPWpGaD
Boceprevir—CTSL—Immune System—CREBBP—esophageal cancer	9.43e-05	0.000416	CbGpPWpGaD
Boceprevir—CTSV—Innate Immune System—EGFR—esophageal cancer	9.4e-05	0.000414	CbGpPWpGaD
Boceprevir—CTSL—Innate Immune System—EGFR—esophageal cancer	9.4e-05	0.000414	CbGpPWpGaD
Boceprevir—CYP3A4—Biological oxidations—CYP26A1—esophageal cancer	9.35e-05	0.000412	CbGpPWpGaD
Boceprevir—CTSS—Innate Immune System—ERBB2—esophageal cancer	9.25e-05	0.000408	CbGpPWpGaD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—ANXA1—esophageal cancer	9.24e-05	0.000407	CbGpPWpGaD
Boceprevir—CTSK—Adaptive Immune System—CDKN1A—esophageal cancer	9.22e-05	0.000406	CbGpPWpGaD
Boceprevir—CYP3A4—Metapathway biotransformation—CYP26A1—esophageal cancer	9.22e-05	0.000406	CbGpPWpGaD
Boceprevir—CTSK—Immune System—TLR4—esophageal cancer	9.15e-05	0.000403	CbGpPWpGaD
Boceprevir—CTSK—Innate Immune System—EP300—esophageal cancer	9.14e-05	0.000403	CbGpPWpGaD
Boceprevir—CTSL—Adaptive Immune System—EGFR—esophageal cancer	9.03e-05	0.000398	CbGpPWpGaD
Boceprevir—CTSV—Adaptive Immune System—EGFR—esophageal cancer	9.03e-05	0.000398	CbGpPWpGaD
Boceprevir—ABCB1—Allograft Rejection—CASP8—esophageal cancer	8.98e-05	0.000396	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—TGFBR2—esophageal cancer	8.96e-05	0.000395	CbGpPWpGaD
Boceprevir—CTSS—Adaptive Immune System—ERBB2—esophageal cancer	8.89e-05	0.000392	CbGpPWpGaD
Boceprevir—CYP3A4—Biological oxidations—GSTO1—esophageal cancer	8.69e-05	0.000383	CbGpPWpGaD
Boceprevir—CYP3A4—Metapathway biotransformation—GSTO1—esophageal cancer	8.57e-05	0.000378	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—SMAD4—esophageal cancer	8.48e-05	0.000374	CbGpPWpGaD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—BUB1B—esophageal cancer	8.45e-05	0.000372	CbGpPWpGaD
Boceprevir—CTSV—Innate Immune System—PIK3CA—esophageal cancer	8.16e-05	0.000359	CbGpPWpGaD
Boceprevir—CTSL—Innate Immune System—PIK3CA—esophageal cancer	8.16e-05	0.000359	CbGpPWpGaD
Boceprevir—CTSL—Immune System—BCL2—esophageal cancer	8.13e-05	0.000358	CbGpPWpGaD
Boceprevir—CTSV—Immune System—BCL2—esophageal cancer	8.13e-05	0.000358	CbGpPWpGaD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—esophageal cancer	8.04e-05	0.000354	CbGpPWpGaD
Boceprevir—ABCB1—Transmembrane transport of small molecules—SLC10A2—esophageal cancer	7.99e-05	0.000352	CbGpPWpGaD
Boceprevir—CTSS—Innate Immune System—CDKN1A—esophageal cancer	7.91e-05	0.000348	CbGpPWpGaD
Boceprevir—CTSL—Immune System—ERBB2—esophageal cancer	7.9e-05	0.000348	CbGpPWpGaD
Boceprevir—CTSV—Immune System—ERBB2—esophageal cancer	7.9e-05	0.000348	CbGpPWpGaD
Boceprevir—CTSK—Immune System—CASP8—esophageal cancer	7.85e-05	0.000346	CbGpPWpGaD
Boceprevir—CTSV—Adaptive Immune System—PIK3CA—esophageal cancer	7.83e-05	0.000345	CbGpPWpGaD
Boceprevir—CTSL—Adaptive Immune System—PIK3CA—esophageal cancer	7.83e-05	0.000345	CbGpPWpGaD
Boceprevir—CTSK—Immune System—CREBBP—esophageal cancer	7.82e-05	0.000344	CbGpPWpGaD
Boceprevir—CTSK—Innate Immune System—EGFR—esophageal cancer	7.79e-05	0.000343	CbGpPWpGaD
Boceprevir—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—esophageal cancer	7.77e-05	0.000342	CbGpPWpGaD
Boceprevir—CTSS—Adaptive Immune System—CDKN1A—esophageal cancer	7.59e-05	0.000335	CbGpPWpGaD
Boceprevir—CTSS—Immune System—TLR4—esophageal cancer	7.54e-05	0.000332	CbGpPWpGaD
Boceprevir—CTSS—Innate Immune System—EP300—esophageal cancer	7.53e-05	0.000332	CbGpPWpGaD
Boceprevir—ABCB1—Transmembrane transport of small molecules—ATP1B2—esophageal cancer	7.51e-05	0.000331	CbGpPWpGaD
Boceprevir—CTSK—Adaptive Immune System—EGFR—esophageal cancer	7.48e-05	0.00033	CbGpPWpGaD
Boceprevir—ABCB1—Transmembrane transport of small molecules—SLC39A6—esophageal cancer	7.12e-05	0.000314	CbGpPWpGaD
Boceprevir—CYP3A4—Biological oxidations—ALDH2—esophageal cancer	7.08e-05	0.000312	CbGpPWpGaD
Boceprevir—ABCB1—HIF-1-alpha transcription factor network—EP300—esophageal cancer	7.03e-05	0.00031	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—HIF1A—esophageal cancer	6.94e-05	0.000306	CbGpPWpGaD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—ABL1—esophageal cancer	6.81e-05	0.0003	CbGpPWpGaD
Boceprevir—ABCB1—Transmembrane transport of small molecules—AQP3—esophageal cancer	6.8e-05	0.000299	CbGpPWpGaD
Boceprevir—CTSK—Innate Immune System—PIK3CA—esophageal cancer	6.76e-05	0.000298	CbGpPWpGaD
Boceprevir—CTSV—Immune System—CDKN1A—esophageal cancer	6.75e-05	0.000297	CbGpPWpGaD
Boceprevir—CTSL—Immune System—CDKN1A—esophageal cancer	6.75e-05	0.000297	CbGpPWpGaD
Boceprevir—CYP3A4—Biological oxidations—GSTT1—esophageal cancer	6.74e-05	0.000297	CbGpPWpGaD
Boceprevir—CTSK—Immune System—BCL2—esophageal cancer	6.74e-05	0.000297	CbGpPWpGaD
Boceprevir—CYP3A4—Biological oxidations—CYP2A6—esophageal cancer	6.66e-05	0.000293	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—KDR—esophageal cancer	6.64e-05	0.000292	CbGpPWpGaD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—SMAD4—esophageal cancer	6.6e-05	0.000291	CbGpPWpGaD
Boceprevir—CTSK—Immune System—ERBB2—esophageal cancer	6.55e-05	0.000288	CbGpPWpGaD
Boceprevir—ABCB1—Transmembrane transport of small molecules—SLC30A7—esophageal cancer	6.52e-05	0.000287	CbGpPWpGaD
Boceprevir—ABCB1—Transmembrane transport of small molecules—ATP4A—esophageal cancer	6.52e-05	0.000287	CbGpPWpGaD
Boceprevir—CTSK—Adaptive Immune System—PIK3CA—esophageal cancer	6.49e-05	0.000286	CbGpPWpGaD
Boceprevir—CTSS—Immune System—CASP8—esophageal cancer	6.46e-05	0.000285	CbGpPWpGaD
Boceprevir—CTSS—Immune System—CREBBP—esophageal cancer	6.44e-05	0.000284	CbGpPWpGaD
Boceprevir—CTSV—Immune System—EP300—esophageal cancer	6.42e-05	0.000283	CbGpPWpGaD
Boceprevir—CTSL—Immune System—EP300—esophageal cancer	6.42e-05	0.000283	CbGpPWpGaD
Boceprevir—CTSS—Innate Immune System—EGFR—esophageal cancer	6.41e-05	0.000283	CbGpPWpGaD
Boceprevir—CYP3A4—Biological oxidations—PTGS1—esophageal cancer	6.31e-05	0.000278	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—NOTCH1—esophageal cancer	6.25e-05	0.000276	CbGpPWpGaD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—BAX—esophageal cancer	6.24e-05	0.000275	CbGpPWpGaD
Boceprevir—CTSS—Adaptive Immune System—EGFR—esophageal cancer	6.16e-05	0.000271	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—BLVRB—esophageal cancer	5.83e-05	0.000257	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—SLC52A3—esophageal cancer	5.83e-05	0.000257	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—CREBBP—esophageal cancer	5.67e-05	0.00025	CbGpPWpGaD
Boceprevir—CTSK—Immune System—CDKN1A—esophageal cancer	5.59e-05	0.000246	CbGpPWpGaD
Boceprevir—CTSS—Innate Immune System—PIK3CA—esophageal cancer	5.57e-05	0.000245	CbGpPWpGaD
Boceprevir—CTSS—Immune System—BCL2—esophageal cancer	5.55e-05	0.000244	CbGpPWpGaD
Boceprevir—CTSV—Immune System—EGFR—esophageal cancer	5.47e-05	0.000241	CbGpPWpGaD
Boceprevir—CTSL—Immune System—EGFR—esophageal cancer	5.47e-05	0.000241	CbGpPWpGaD
Boceprevir—CTSS—Immune System—ERBB2—esophageal cancer	5.39e-05	0.000237	CbGpPWpGaD
Boceprevir—CYP3A4—Biological oxidations—CYP1B1—esophageal cancer	5.37e-05	0.000237	CbGpPWpGaD
Boceprevir—CTSS—Adaptive Immune System—PIK3CA—esophageal cancer	5.35e-05	0.000236	CbGpPWpGaD
Boceprevir—CTSK—Immune System—EP300—esophageal cancer	5.32e-05	0.000235	CbGpPWpGaD
Boceprevir—CYP3A4—Metapathway biotransformation—CYP1B1—esophageal cancer	5.3e-05	0.000233	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—NOS3—esophageal cancer	5.08e-05	0.000224	CbGpPWpGaD
Boceprevir—CYP3A4—Biological oxidations—CYP19A1—esophageal cancer	5.05e-05	0.000222	CbGpPWpGaD
Boceprevir—CYP3A4—Metapathway biotransformation—CYP19A1—esophageal cancer	4.98e-05	0.000219	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—SLC10A2—esophageal cancer	4.96e-05	0.000219	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—CA1—esophageal cancer	4.96e-05	0.000219	CbGpPWpGaD
Boceprevir—ABCB1—Transmembrane transport of small molecules—ABCC2—esophageal cancer	4.94e-05	0.000218	CbGpPWpGaD
Boceprevir—CTSV—Immune System—PIK3CA—esophageal cancer	4.75e-05	0.000209	CbGpPWpGaD
Boceprevir—CTSL—Immune System—PIK3CA—esophageal cancer	4.75e-05	0.000209	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—ERBB2—esophageal cancer	4.75e-05	0.000209	CbGpPWpGaD
Boceprevir—CTSS—Immune System—CDKN1A—esophageal cancer	4.61e-05	0.000203	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—CA2—esophageal cancer	4.54e-05	0.0002	CbGpPWpGaD
Boceprevir—CTSK—Immune System—EGFR—esophageal cancer	4.54e-05	0.0002	CbGpPWpGaD
Boceprevir—ABCB1—Transmembrane transport of small molecules—GNG7—esophageal cancer	4.48e-05	0.000197	CbGpPWpGaD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—CASP8—esophageal cancer	4.43e-05	0.000195	CbGpPWpGaD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—CREBBP—esophageal cancer	4.41e-05	0.000194	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—SLC52A3—esophageal cancer	4.4e-05	0.000194	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—BLVRB—esophageal cancer	4.4e-05	0.000194	CbGpPWpGaD
Boceprevir—CTSS—Immune System—EP300—esophageal cancer	4.38e-05	0.000193	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—PLCE1—esophageal cancer	4.22e-05	0.000186	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—ADH7—esophageal cancer	4.22e-05	0.000186	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—CCND1—esophageal cancer	4.19e-05	0.000185	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—CDKN1A—esophageal cancer	4.06e-05	0.000179	CbGpPWpGaD
Boceprevir—CTSK—Immune System—PIK3CA—esophageal cancer	3.94e-05	0.000173	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—EP300—esophageal cancer	3.86e-05	0.00017	CbGpPWpGaD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—BCL2—esophageal cancer	3.8e-05	0.000168	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—CA1—esophageal cancer	3.74e-05	0.000165	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—SLC10A2—esophageal cancer	3.74e-05	0.000165	CbGpPWpGaD
Boceprevir—CTSS—Immune System—EGFR—esophageal cancer	3.74e-05	0.000165	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—ADH1B—esophageal cancer	3.7e-05	0.000163	CbGpPWpGaD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—esophageal cancer	3.69e-05	0.000163	CbGpPWpGaD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—esophageal cancer	3.61e-05	0.000159	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—TYMP—esophageal cancer	3.53e-05	0.000156	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—CYP26A1—esophageal cancer	3.44e-05	0.000152	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—CA2—esophageal cancer	3.42e-05	0.000151	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—MYC—esophageal cancer	3.36e-05	0.000148	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—ALOX15—esophageal cancer	3.35e-05	0.000148	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—EGFR—esophageal cancer	3.29e-05	0.000145	CbGpPWpGaD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—esophageal cancer	3.26e-05	0.000144	CbGpPWpGaD
Boceprevir—CTSS—Immune System—PIK3CA—esophageal cancer	3.24e-05	0.000143	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—GSTO1—esophageal cancer	3.2e-05	0.000141	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—TPI1—esophageal cancer	3.2e-05	0.000141	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—PLCE1—esophageal cancer	3.18e-05	0.00014	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—ADH7—esophageal cancer	3.18e-05	0.00014	CbGpPWpGaD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—esophageal cancer	3.16e-05	0.000139	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—ALDOB—esophageal cancer	3.06e-05	0.000135	CbGpPWpGaD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—esophageal cancer	3e-05	0.000132	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—GAPDH—esophageal cancer	2.95e-05	0.00013	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—CRABP1—esophageal cancer	2.92e-05	0.000129	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—PIK3CA—esophageal cancer	2.86e-05	0.000126	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—ADH1B—esophageal cancer	2.79e-05	0.000123	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—GNG7—esophageal cancer	2.78e-05	0.000123	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—TP53—esophageal cancer	2.76e-05	0.000122	CbGpPWpGaD
Boceprevir—ABCB1—Transmembrane transport of small molecules—HMOX1—esophageal cancer	2.73e-05	0.00012	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—BLVRB—esophageal cancer	2.71e-05	0.00012	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—SLC52A3—esophageal cancer	2.71e-05	0.00012	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—TYMP—esophageal cancer	2.67e-05	0.000118	CbGpPWpGaD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—esophageal cancer	2.62e-05	0.000115	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—ALDH2—esophageal cancer	2.61e-05	0.000115	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—CYP26A1—esophageal cancer	2.59e-05	0.000114	CbGpPWpGaD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—esophageal cancer	2.56e-05	0.000113	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—ALOX15—esophageal cancer	2.53e-05	0.000111	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—GSTT1—esophageal cancer	2.48e-05	0.000109	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—CYP2A6—esophageal cancer	2.45e-05	0.000108	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—TPI1—esophageal cancer	2.41e-05	0.000106	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—GSTO1—esophageal cancer	2.41e-05	0.000106	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—ENO1—esophageal cancer	2.32e-05	0.000102	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—PTGS1—esophageal cancer	2.32e-05	0.000102	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—ALDOB—esophageal cancer	2.31e-05	0.000102	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—SLC10A2—esophageal cancer	2.31e-05	0.000102	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—CA1—esophageal cancer	2.31e-05	0.000102	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—PSME1—esophageal cancer	2.29e-05	0.000101	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—PSME2—esophageal cancer	2.29e-05	0.000101	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—GAPDH—esophageal cancer	2.23e-05	9.81e-05	CbGpPWpGaD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—esophageal cancer	2.22e-05	9.79e-05	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—CRABP1—esophageal cancer	2.21e-05	9.72e-05	CbGpPWpGaD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	2.15e-05	9.47e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—CA2—esophageal cancer	2.11e-05	9.29e-05	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—GNG7—esophageal cancer	2.1e-05	9.25e-05	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—CYP1B1—esophageal cancer	1.97e-05	8.7e-05	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—ALDH2—esophageal cancer	1.97e-05	8.66e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—PLCE1—esophageal cancer	1.96e-05	8.64e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—ADH7—esophageal cancer	1.96e-05	8.64e-05	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—GSTT1—esophageal cancer	1.87e-05	8.24e-05	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—CYP19A1—esophageal cancer	1.86e-05	8.18e-05	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—CYP2A6—esophageal cancer	1.85e-05	8.15e-05	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—PTGS1—esophageal cancer	1.75e-05	7.72e-05	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—ENO1—esophageal cancer	1.75e-05	7.72e-05	CbGpPWpGaD
Boceprevir—ABCB1—Transmembrane transport of small molecules—CREBBP—esophageal cancer	1.75e-05	7.72e-05	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—PSME1—esophageal cancer	1.73e-05	7.61e-05	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—PSME2—esophageal cancer	1.73e-05	7.61e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—ADH1B—esophageal cancer	1.72e-05	7.58e-05	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—HMOX1—esophageal cancer	1.69e-05	7.47e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—TYMP—esophageal cancer	1.64e-05	7.24e-05	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—ABCB1—esophageal cancer	1.63e-05	7.17e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—CYP26A1—esophageal cancer	1.6e-05	7.04e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—ALOX15—esophageal cancer	1.56e-05	6.86e-05	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—CYP1B1—esophageal cancer	1.49e-05	6.57e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—GSTO1—esophageal cancer	1.49e-05	6.55e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—TPI1—esophageal cancer	1.49e-05	6.55e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—ALDOB—esophageal cancer	1.42e-05	6.28e-05	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—CYP19A1—esophageal cancer	1.4e-05	6.17e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—GAPDH—esophageal cancer	1.37e-05	6.04e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—CRABP1—esophageal cancer	1.36e-05	5.99e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—GNG7—esophageal cancer	1.29e-05	5.7e-05	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—HMOX1—esophageal cancer	1.28e-05	5.63e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—ALDH2—esophageal cancer	1.21e-05	5.34e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—GSTT1—esophageal cancer	1.15e-05	5.08e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—CYP2A6—esophageal cancer	1.14e-05	5.02e-05	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—CREBBP—esophageal cancer	1.09e-05	4.79e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—ENO1—esophageal cancer	1.08e-05	4.76e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—PTGS1—esophageal cancer	1.08e-05	4.76e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—PSME1—esophageal cancer	1.06e-05	4.69e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—PSME2—esophageal cancer	1.06e-05	4.69e-05	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—NOS3—esophageal cancer	9.73e-06	4.29e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—CYP1B1—esophageal cancer	9.18e-06	4.05e-05	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—PTGS2—esophageal cancer	8.9e-06	3.92e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—CYP19A1—esophageal cancer	8.63e-06	3.8e-05	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—CREBBP—esophageal cancer	8.2e-06	3.61e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—HMOX1—esophageal cancer	7.88e-06	3.47e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—ABCB1—esophageal cancer	7.56e-06	3.33e-05	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—EP300—esophageal cancer	7.4e-06	3.26e-05	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—NOS3—esophageal cancer	7.34e-06	3.24e-05	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—PTGS2—esophageal cancer	6.72e-06	2.96e-05	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—EP300—esophageal cancer	5.59e-06	2.46e-05	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—PIK3CA—esophageal cancer	5.48e-06	2.41e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—CREBBP—esophageal cancer	5.05e-06	2.23e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—NOS3—esophageal cancer	4.52e-06	1.99e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—PTGS2—esophageal cancer	4.14e-06	1.82e-05	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—PIK3CA—esophageal cancer	4.13e-06	1.82e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—EP300—esophageal cancer	3.44e-06	1.52e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—PIK3CA—esophageal cancer	2.55e-06	1.12e-05	CbGpPWpGaD
